Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-08-22
1997-03-18
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514810, 514813, A61K 3144
Patent
active
056123574
ABSTRACT:
A pharmaceutical composition is provided that is useful to alleviate various symptoms of tobacco withdrawal syndrome comprising an amount of cotinine or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, which amount is effective to reduce or eliminate at least one of the symptoms of tobacco withdrawal syndrome in a human.
REFERENCES:
patent: 2981641 (1961-04-01), O'Neill
patent: 3048520 (1962-08-01), McKennis et al.
patent: 3867519 (1975-02-01), Michaels
patent: 3870791 (1975-03-01), Haddad et al.
patent: 3870794 (1975-03-01), Hutchinson et al.
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4136177 (1979-01-01), Lin et al.
patent: 4140122 (1979-02-01), Kuhl et al.
patent: 4255415 (1981-03-01), Chrai et al.
patent: 4383529 (1983-05-01), Webster
patent: 4621074 (1986-11-01), Bourne
patent: 4668506 (1987-05-01), Bawa
patent: 4713244 (1987-12-01), Bawa et al.
patent: 4748181 (1988-05-01), Hutchinson et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4835162 (1989-05-01), Abood
patent: 4931279 (1990-06-01), Bawa et al.
patent: 4966916 (1990-10-01), Abood
J.G. Liberto et al., "Cotinine in the Treatment of Cigarette Smoking," Poster Presented at the American Society for Addiction Medicine 8th National Conference on Nicotine Dependence, Toronto, Ontario, Canada, Oct. 14, 1995.
P. Jacob et al., "Disposition kinetics of nicotine and cotinine enantiomers in rabbits and beagle dogs," J. Pharmaceutical Sciences, 77, 396-400 (1988).
B. Kuo et al., "Influence of nicotine and cotinine on the expression of plasminogen activator activity in bovine aortic endothelial cells," Thromb. Haemostasis, 61, 70-79 (1989).
G. Kyerematen et al., "Disposition of nicotine and eight metabolites in smokers and nonsmokers: identification in smokers of two metabolites that are longer lived than nicotine," Clin. Pharmacol. Ther., 48, 641-651 (1990).
W. Luck et al., "Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers," Dev. Pharmacol. Ther., 8, 384-395 (1985).
C. Lynch et al., "Spontaneous cigarette brand switching: consequences for nicotine and carbon monoxide exposure," Am. J. Public Health, 78, 1191-1194 (1987).
R. C. O'Neill, "Tobacco products containing nicotine antagonists," Chemical Abstracts, 55, 16920 (1961).
E. Rylander et al., "Exposure to environmental tobacco smoke and urinary excretion of cotinine and nicotine in children," Acta Poediatr. Scand., 78, 449-450 (1989).
I. Sasson et al., "Cigarette smoking and neoplasia of the uterine cervix: smoke constitiuents in cervical mucus," New England J. Med., 312, 315-316 (1985).
K. Takada, et al., "Discriminitive stimulus effects of intravenous l-nicotine and nicotine analogs or metabolites on squirrel monkeys," Psychopharmacology, 99, 208-212 (1989).
B. Testa et al., "Circular Dichroic determination of the preferred conformation of nicotine and related chiral alkaloids in aqueous solution," Mol. Pharmacol., 9, 10-16 (1973).
R. Barbieri et al., "Cotinine and nicotine inhibit human fetal adrenal 11.beta.-hydroxylase," J. Clin. Endocrinol. Metab., 69, 1221-1224 (1989).
A. H. Beckett et al., "A possible relationship between pKal and lipid solubility and the amounts secreted in urine to some tobacco alkaloids given to man," J. Pharma. Pharmacol., 24, 115-120 (1972).
M. Curvall et al., "The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers," Eur. J. Clin. Pharmacol., 38, 281-287 (1990).
M. Curvall et al., "Stimulation and evaluation of nicotine intake during passive smoking: cotinine measurements in body fluids of nonsmokers given intravenous infusions of nicotine," Clin. Pharmacol. Ther., 47, 42-49 (1990).
J. Gabrielsson et al., "Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat," J. Pharmacokinetics Biopharmaceutics, 15, 583-599 (1987).
R. Galeazzi et al., "Steady-stroke concentration of cotinine as a measure of nicotine-intake by smokers," Eur. J. Clin. Pharmacol., 28, 301-304 (1985).
R. R. Hutchinson et al., "Effects of nicotine on avoidance, conditioned suppression and aggression response measures in animals and man," In: Smoking Behavior: Motives and Incentives, W. L. Dunn (ed.), V. H. Winston & Sons, Washington, D.C. pp. 171-196 (1973).
"Tobacco Products Containing Nicotine Antagonists", Chemical Abstracts, 55, col. 16920 (1961).
United States Department of Health and Human Services, The Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General, U.S. Govt. Print. Off., Washington D.C., DHHS Pub. No. (CDC) 88-8406, pp. 197-208 (1988).
T. Weiss et al., "Cotinine levels in follicular fluid and serum of IVF patients: effect on granulosa-luteal cell function in vitro", Human Reproduction, 4, 482-485 (1989).
K. Yamamoto et al., "Nicotine-Induced EEG and Behavioral Arousal", Int. J. Neuropharmacol., 4, 359-373 (1965).
J. Yeh et al., "Nicotine and Cotinine Inhibit Rat Testis Androgen Biosynthesis In Vitro", J. steroid Biochem., 33, 627-630 (1989).
P. Zeidenberg et al., Abstract of "Nicotine: Cotinine Levels in Blood During Cessation of Smoking", Comp. Psychiatry, 18, 93-111 (1977).
T. Patterson et al., "Nicotine and Cotinine Inhibit Steroidogenesis in Mouse Leydig Cells", Life Sciences, 46, 2650272 (1990).
C. Rahn et al., "Correlations Between Urinary Nicotine or Cotinine and Urinary Mutagenicity in Smokers on Controlled Diets", Environ. Molec. Mutagenesis, 17, 244-252 (1991).
M. Riebe et al., "Mutagenicity testing, in bacterial test systems, of some constituents of tobacco", Mutation Research, 101, 39-43 (1982).
M. Risner et al., "Effects of Nicotine, Cocaine and Some of Their Metabolites on Schedule-Controlled Responding by Beagle Dogs and Squirrel Monkeys", J. Pharmacol. and Exp. Ther., 234, 113-119 (1985).
G. Scherer et al., "Pharmacokinetics of Nicotine, Cotinine and 3'-Hydroxycotinine in Cigarette Smokers", Klin Wochenschr, 66, 5-11 (1988).
S. Schwartz et al., "Studies on the Degradation of the Pyrrolidine Ring of (-)-Nicotine in Vivo", J. Biol. Chem., 238, 1807-1812 (May 1963).
D. Sepkovic et al., "Biomedical Applications of Cotinine Quantitation in Smoking Related Research", AJPH, 75, 663-665 (Jun. 1985).
E. Srivastava et al., "Effect of Nicotine and Cotinine on the Production of Oxygen Free Radicals by Neutrophils in Smokers and Non-smokers", Human Toxicology, 8, 461-463 (1989).
S. Tiffany et al., "The development and initial validation of a questionnaire on smoking urges", British J. of Addiction, 86, 1467-1476 (1991).
J. Hughes et al., "Effects of Abstinence from Tobacco A Critical Review", Research Advances in Alcohol and Drug Problems, 10, 317-398 (1990).
K. Kim et al., "Effects of Some Nicotine Metabolites and Related Compounds on Isolated Smooth Muscle", J. Pharm. Exper. Therapeutics, 161, 59-69 (1968).
G. Kyerematen et al., "Time-Dependent Induction of Hepatic Drug Metabolism in Rats by Cotinine", Life Sciences, 32, 551-556 (1983).
E. LaVoie et al., "Evaluation of the Effects of Cotinine and Nicotine-N'-oxides on the Development of Tumors in Rats Initiated With N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide", J. Natl. Cancer Inst., 75, 1075-1081 (Dec. 1985).
W. Martin et al., "Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man", Clinical Pharmacology and Therapeutics, 12, 245-258 (1971).
H. McKennis Jr. et al., "N-Methylation of Nicotine and Cotinine in Vivo", J. Biol. Chem., 238, 719-723 (Feb. 1963).
H. McKennis Jr. et al., "Alternate Routes in the Metabolic Degradation of the Pyrrolidine Ring of Nicotine", J. Biol. Chem., 239, 3990-3996 (Nov. 1964).
A. Meikle et al., "Nicotine and Cotinine Effects on 3Alpha Hydroxysteroid Dehydrogenase in Canine Prostate", Life Sciences, 43, 1845-1850 (1988).
D. Dawson et al., "Evaluation of the Developmental Toxicity of Nicotine and Cotinine with Frog Embryo Teratogenesis Assay: Xenopus", Teratogenesis, Carcinogenesis and Mutagenes
Hatsukami Dorothy K.
Keenan Robert M.
Pharmaco Behavioral Associates, Inc.
Weddington Kevin E.
LandOfFree
Use of cotinine to assist in the cessation of tobacco smoking does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cotinine to assist in the cessation of tobacco smoking, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cotinine to assist in the cessation of tobacco smoking will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1706618